Ligand-driven enhancer activation selectively boosts target gene expression while indirectly repressing neighboring non-target genes, revealing dynamic and competitive regulation during early ...

In people with severely compromised immune systems, JC polyomavirus can trigger an untreatable, often fatal brain disease. An ...

Researchers from Heinrich Heine University Düsseldorf (HHU) have taken an important step toward developing intelligent ...

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR ...

A new study reveals the dynamics of photosynthesis at the cellular level. Led by co-authors Professor Barry Bruce and ...

Under the terms, Ligand will pay $39 a share in cash for Xoma, a 2.9% premium over the $37.90 closing price on Friday. The deal is expected to close in the third quarter.

April 27 (Reuters) - Ligand Pharmaceuticals (LGND.O), opens new tab will buy fellow biotechnology royalty aggregator XOMA Royalty (XOMA.O), opens new tab for about $739 million in cash, the companies ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its peer Ligand Pharmaceuticals. On Monday, Ligand announced plans to acquire ...

Ligand Pharmaceuticals continues to outperform, driven by its high-margin, diversified royalty model and disciplined investment approach. LGND’s transition in 2022 to a capital and technology provider ...

A GPS-like technique has been used to track G protein-coupled receptor movement, revealing how these essential receptors function. Although G protein-coupled receptors (GPCRs) are crucial to the ...

Abstract: Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically ...